Originally published 2019-02-13.

In late January 2019 a small Israeli biotech firm, Accelerated Evolution Biotechnologies (AEBi), told reporters it expected to offer "a complete cure for cancer" within about a year. The treatment, called MuTaTo, had been tested only in mice, and the company had published no data in a medical journal. Cancer specialists warned straight away that the promise was not supported by evidence, and in the years since no peer-reviewed human trial results for MuTaTo have appeared that we could find.
The story spread across the world in days, from tabloids to mainstream news sites. Looking back at it is useful, not to mock a company with an interesting idea, but because it shows exactly how a "cancer cure" headline is born and what questions to ask the next time one appears.
What AEBi actually announced
The claim first appeared in The Jerusalem Post. AEBi's board chairman, Dan Aridor, said the company believed it would deliver a complete cure in a year's time, and that lung cancer would be its first target. The company described the treatment as effective from the first day, short in duration, low in side effects and cheaper than many existing drugs, and suggested it could be both generic and personalised.
The company's chief executive, Dr Ilan Morad, gave a more modest picture when asked for details. He told CNBC that AEBi had finished only its first exploratory experiment in mice, which he said had slowed the growth of cancer cells. Results had been shown as posters or abstracts at drug discovery conferences. Asked by The Times of Israel why nothing had been published in a journal, Morad replied: "We can't afford it."
How MuTaTo was supposed to work
MuTaTo stands for "multi-target toxin". The idea was to attach several short protein fragments, called peptides, to a powerful toxin. Each peptide would latch onto a different receptor found on the surface of cancer cells. Because the drug hit several targets at once, the company argued, tumours would struggle to develop resistance by mutating a single receptor, much as combination therapy changed the outlook for HIV.
The peptides were found using AEBi's in-house platform, called SoAP, which is based on phage display: a laboratory method that uses viruses that infect bacteria to screen huge libraries of peptides for ones that stick to a chosen target. Phage display is a real and powerful technique. Its pioneers shared the 2018 Nobel Prize in Chemistry, and the blockbuster arthritis drug adalimumab (Humira) was discovered with it. The company also argued that small peptides would be less likely to provoke the immune system than larger antibodies.
None of that is unreasonable as a research direction. The problem was the leap from "promising idea" to "cure in a year".
Why experts were sceptical
Oncologists, researchers and science writers raised the same core objections:
- Mice are not people. Most treatments that shrink tumours in mice fail in human trials, either because they do not work or because they prove too toxic.
- No published data. Conference posters receive little scrutiny. Without full methods and results in a peer-reviewed journal, outsiders could not judge the experiments.
- Toxicity. The surgeon and blogger David Gorski pointed out that hitting several receptors with a strong toxin could easily increase side effects rather than reduce them, and that the company's own early data showed the compound building up in the kidneys.
- Cancer is many diseases. Hundreds of cancer types behave differently. A single cure for all of them would be unlike anything in the history of medicine.
Dr Ben Neel, a cancer specialist at NYU Langone in New York, said it was very unlikely the firm had found a cure and described such announcements as "cruel false promises". The American Cancer Society's deputy chief medical officer, Dr J. Leonard Lichtenfeld, wrote that there was no realistic way to move from mouse studies to a proven cure in less than a year.
How long it really takes to prove a cancer drug
A new medicine normally passes through several stages before any regulator approves it:
- Preclinical work in cells and animals to check that the drug does something useful and is reasonably safe.
- Phase 1 trials in a small number of patients, mainly to find a safe dose.
- Phase 2 trials to see whether the drug shrinks tumours or slows disease.
- Phase 3 trials comparing the drug with the current standard treatment in hundreds or thousands of patients.
Les Funtleyder, a health-care fund manager, told CNBC that even with fast-track permissions from the US Food and Drug Administration, moving a cancer drug from mouse experiments to pharmacy shelves can take six to seven years. He added that he would not believe the claim without good human evidence. In 2019 AEBi had not yet completed step one.
Why the headline spread so fast
Cancer touches almost every family. According to the World Health Organization, it causes nearly 10 million deaths a year, close to one in six deaths worldwide. Any hint of a universal cure is going to be shared by people who desperately want it to be true.
The original reports also had ingredients that travel well online: a confident quote, a catchy name, a comparison with HIV, and a short deadline. Some outlets later ran follow-ups with doubtful experts, but the corrections never travelled as far as the first wave of headlines.
What happened next
The promised year passed without a cure. AEBi said at the time that it planned to begin human testing, but as far as we could find, no results from a MuTaTo clinical trial have been published in a peer-reviewed journal since. That does not prove the approach is worthless; many good ideas take a decade or more to reach patients, and many more never do. It does mean the 2019 promise of a complete cure within a year did not come true.
Meanwhile, real progress in cancer has come gradually: immunotherapies, targeted drugs matched to specific mutations, better screening and steep falls in smoking. The WHO estimates that around 38% of cancers could be prevented by avoiding known risk factors and using proven prevention measures.
How to judge the next "cancer cure" headline
A few quick checks separate genuine advances from hype:
- Was the treatment tested in people, or only in cells and animals?
- Have the results been published in a peer-reviewed journal, and how many patients took part?
- Which specific cancer is involved? Claims that one drug cures every cancer deserve extra doubt.
- Do independent experts, not just the company or its investors, sound excited?
- Is anything being sold, or is money being requested, on the strength of the claim?
If you or someone you love has cancer, talk to the treating doctor before acting on any news story, and ask whether a suitable clinical trial is open.
Sources: CNBC, 29 January 2019: Israeli company that claims cancer cure faces skeptical US market; Respectful Insolence (David Gorski), 31 January 2019; World Health Organization: Cancer fact sheet.

COMMENTS